Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial

Published:2016-09-16 Issue:3 Volume:17 Page:682-691
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Kulkarni S.¹²,Kirkiles-Smith N. C.³,Deng Y. H.⁴,Formica R. N.¹²,Moeckel G.⁵,Broecker V.⁶,Bow L.¹,Tomlin R.¹,Pober J. S.³⁵

Affiliation:

1. Department of Surgery; Yale School of Medicine; New Haven CT

2. Department of Medicine; Yale School of Medicine; New Haven CT

3. Department of Immunobiology; Yale School of Medicine; New Haven CT

4. Center for Analytical Science; Yale School of Public Health; New Haven CT

5. Department of Pathology; Yale School of Medicine; New Haven CT

6. Department of Pathology; University of Cambridge; Cambridge UK

Funder

Alexion Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajt.14001/fullpdf

Reference25 articles.

1. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients;Port;JAMA,1993

2. A study of the quality of life and cost-utility of renal transplantation;Laupacis;Kidney Int,1996

3. Risk factors for retransplant kidney recipients: Relisting and outcomes from patients’ primary transplant;Heaphy;Am J Transplant,2014

4. OPTN/SRTR 2014 Annual Data Report: Kidney;Hart;Am J Transplant,2016

5. Humoral theory of transplantation;Terasaki;Am J Transplant,2003

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interchain disulfide engineering enables the efficient production of functional HLA-DQ-Fc fusion proteins;Journal of Biological Chemistry;2024-09

2. Chronic Rejection After Kidney Transplantation;Transplantation;2024-08-28

3. Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications;Transplant International;2024-08-12

4. Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series;Transplant International;2024-08-01

5. Felzartamab and Antibody-Mediated Rejection in Kidney Transplants — Hope at Last?;New England Journal of Medicine;2024-07-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3